Open Access
Dehydroxymethylepoxyquinomicin selectively ablates T-CAEBV cells
Hui Zhang1,3,Wen-Tao Yang2,Zhao Wang2,Chun-Mei Yao1,Xiao-Fang Wang1,Zhi-Qing Tian3,Ying-Ying Jin4,Lin-Lin Wang4,Tong-Xin Chen1,*
Department of Pediatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (SJTU-SM), 1665 Kongjiang Road, Shanghai 200092, China
State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (SJTU-SM), 197 Ruijin Road II, Shanghai 200025, China
Department of Pediatrics, The First Affiliated Hospital of Guangzhou Medical University, 151 West Yanjiang Rd, Guangzhou, 510120, China
DOI: 10.2741/4322 Volume 20 Issue 3, pp.502-514
Published: 01 January 2015
(This article belongs to the Special Issue Cellular immunology and stem cell biology)
*Corresponding Author(s):  
Tong-Xin Chen

Chronic active Epstein-Barr virus infection (CAEBV) represents a new subtype of lymphoproliferative disorders characterized by high morbidity and mortality rates and often leads to malignant transformation of infected cells. Efficient therapeutic strategies are presently unavailable; therefore, the development of therapies to prevent CAEBV-mediated transformation and disease progression is crucial. Here, we used microarray analysis and luciferase reporter assays to reveal the potential role of activated nuclear factor kappa B (NF-κB) in T cell type of-CAEBV infection. Using a series of cellular and molecular experiments, we demonstrated that dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, can selectively induce apoptosis in SNT-16 cells infected with CAEBV. Mechanistic studies suggested that DHMEQ induces SNT-16 cell apoptosis through NF-κB inhibition coupled with oxidative stress generation. Thus, activated NF-κB could be a new target for CAEBV therapeutics. Owing to its selective targeting ability, DHMEQ may be a candidate for a novel therapeutic regimen to control the progression of CAEBV infections.

Key words
Dehydroxymethylepoxyquinomicin,Oxidative Stress,Chronic active Epstein-Barr Virus Infection,Signaling,Apoptosis,Induction,NF-kappaB,Activation,Review
Share and Cite
Hui Zhang, Wen-Tao Yang, Zhao Wang, Chun-Mei Yao, Xiao-Fang Wang, Zhi-Qing Tian, Ying-Ying Jin, Lin-Lin Wang, Tong-Xin Chen. Dehydroxymethylepoxyquinomicin selectively ablates T-CAEBV cells. Frontiers in Bioscience-Landmark. 2015. 20(3); 502-514.